Data protection is the commercial backbone of a veterinary development programme. Regulation (EU) 2019/6 replaces the old uniform periods with species-based protection that can be extended, but only within a ceiling.
The base periods
Article 39 sets the protection of technical documentation, counted from the day the marketing authorisation is granted under Article 5(1):
- 10 years for cattle, sheep for meat production, pigs, chickens, dogs and cats;
- 14 years for antimicrobial products for those species, where the active substance was not already in an authorised veterinary medicinal product in the Union when the application was submitted;
- 18 years for bees;
- 14 years for other species.
During this period, other applicants cannot rely on your protected documentation for a generic application under Article 18.
Extensions under Article 40
- One additional year for each further major species added by variation or new authorisation, for the species groups covered by Article 39(1)(a) and (b).
- Four additional years for further species in the “other species” category.
- For extensions obtained through a variation, the application must be submitted at least three years before the relevant protection period expires.
Total protection from the first authorisation, including extensions, may not exceed 18 years.
Related protections
Article 40 also provides that safety, residue, pre-clinical and clinical data submitted with a maximum residue limit application under Regulation (EC) No 470/2009 cannot be relied on by other applicants for five years from the authorisation, unless a letter of access is given. A variation changing the pharmaceutical form, route or dosage can earn four years of protection for the supporting studies where it is assessed as reducing antimicrobial or antiparasitic resistance or improving the benefit-risk balance.
Planning implications
- Diarise the three-year pre-expiry window for species-extension variations; missing it forfeits the extension.
- Check whether line extensions fall within the same overall authorisation for protection purposes.
- Generic and hybrid applicants should confirm that the reference product protection has elapsed, or will elapse in less than two years, before relying on Article 18.
Commercial perspective
Protection periods only matter if they are tracked. A portfolio view should list each product, its first authorisation date, the applicable base period under Article 39, any extension already obtained and the last date on which an extension variation can still be submitted. Business development teams can then see which products are approaching generic entry and which have room for a species extension.
For generic and hybrid applicants, the same calendar shows when a reference product’s documentation becomes available for reliance. Remember that bioequivalence, Annex II requirements and any additional studies for hybrids still have to be addressed in the dossier; expiry of protection removes a barrier but does not replace the application content.
How PQRA helps
PQRA maps protection timelines for originator portfolios, flags the dates that govern species-extension strategy, and helps generic and hybrid applicants assess when a reference product opens for reliance and what the dossier must contain.
Contact PQRA to discuss protection timelines and lifecycle planning for your veterinary portfolio.


No responses yet